Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the european organization for research and treatment of cancer gastrointestinal tract cancer cooperative group

Journal of Clinical Oncology

Volumn 18, Issue 14, 2000, Pages 2648-2657

  Vanhoefer, Udo ^a   Rougier, Philippe ^a   Wilke, Hansjochen ^a   Ducreux, Michel P ^a   Lacave, Angel J ^a   Van Cutsem, Eric ^a   Planker, Manfred ^a   Dos Santos Guimaraes, José ^a   Piedbois, Pascal ^a   Paillot, Bernard ^a   Bodenstein, Heinrich ^a   Schmoll, Hans Jochen ^a   Bleiberg, Harry ^a   Nordlinger, Bernard ^a   Couvreur, Marie Laure ^a   Baron, Benoit ^a   Wils, Jacques A ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; METHOTREXATE;

ADULT; ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; DIARRHEA; DIGESTIVE SYSTEM CANCER; DRUG EFFICACY; FEMALE; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; STOMACH CANCER; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 0033909505     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2000.18.14.2648     Document Type: Article

References (39)

1. Diehl JT, Hermann RE, Cooperman AM, et al: Gastric carcinoma: A ten-year review. Ann Surg 198:9-12, 1983
2. McNeer G, Vandenberg H, Donn FY: A critical evaluation of subtotal gastrectomy for the cure of cancer of the stomach. Ann Surg 134:1-7, 1951
3. Gunderson LL, Sosin H: Adenocarcinoma of the stomach: Areas of failure in a reoperation series (second or symptomatic look) -Clinicopathologic correlation and implications for adjuvant therapy. Int J Radiat Oncol Biol Phys 8:1-11, 1982
4. Dupont JB Jr, Lee JR, Burton GR, et al: Adenocarcioma of the stomach: Review of 1,497 cases. Cancer 41:941-947, 1978
5. Pyrhönen S, Kuitunen T, Kouri M: A randomized phase III trial comparing fluorouracil, epidoxorubicin and methotrexate (FEMTX) with best supportive care in non-resectable gastric cancer. Ann Oncol 3:12, 1992 (suppl 5, abstr 47)
6. Glimelius B, Ekström K, Hoffman K, et al: Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 8:163-168, 1997
7. Murad AM, Santiago FF, Petroianu A, et al: Modified therapy with 5-fluorouracil, doxorubicin and methotrexate in advanced gastric cancer. Cancer 72:37-41, 1993
8. Akoh JA, Mcintyre IMC: Improving survival in gastric cancer: Review of 5-year survival rates in English language publications from 1970. Br J Surg 79:293-299, 1992
9. Klein HO, Wickramanayake PD, Dieterle F, et al: High-dose MTX/5FU and adriamycin for gastric cancer. Semin Oncol 10:29-31, 1983 (suppl 2)
10. Wils J, Bleiberg H, Dalesio O, et al: An EORTC Gastrointestinal Group evaluation of the combination of sequential methotrexate and 5-fluorouracil, combined with adriamycin in advanced measurable gastric cancer. J Clin Oncol 4:1799-1803, 1986
11. Wils JA, Klein HO, Wagener DJT, et al: Sequential high-dose methotrexate and fluorouracil combined with doxorubicin: A step ahead in the treatment of advanced gastric cancer - A trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group. J Clin Oncol 9:827-831, 1991
12. Kelsen D, Karpeh M, Schwartz G, et al: Neoadjuvant therapy of high-risk gastric cancer: A phase II trial of preoperative FAMTX and postoperative intraperitoneal fluorouracil-cisplatin plus intravenous fluorouracil. J Clin Oncol 14:1818-1828, 1996
13. Webb A, Cunningham D, Scarffe JH, et al: Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol 15:261-267, 1997
14. Wilke H, Preusser P, Fink U, et al: High-dose folinic acid/ etoposide/5-fluorouracil in advanced gastric cancer: A phase II study in elderly patients or patients with cardiac risk. Invest New Drugs 8:65-70, 1990
15. Wilke H, Preusser P, Stahl M, et al: Etoposide, folinic acid, and 5-fluorouracil in carboplatin-pretreated patients with advanced gastric cancer. Cancer Chemother Pharmacol 29:83-84, 1991
16. di Bartolomeo M, Bajetta E, de Braud F, et al: Phase II study of the etoposide, leucovorin and fluorouracil combination for patients with advanced gastric cancer unsuitable for aggressive chemotherapy. Oncology 52:41-44, 1995
17. Au E, Koo WH, Tan EH, et al: A phase II trial of etoposide. leucovorin and 5-fluorouracil (ELF) in patients with advanced gastric cancer. J Chemother 8:300-303, 1996
18. Van Cutsem E, Filez L, Dewyspelaere J, et al: Etoposide, leucovorin and 5-fluorouracil in advanced gastric cancer: A phase II study. Anticancer Res 15:1079-1080, 1995
19. Taal BG, Teller FGM, ten Bokkel Huinink WW, et al: Etoposide, leucovorin, 5-fluorouracil (ELF) combination chemotherapy for advanced gastric cancer: Experience with two treatment schedules incorporating intravenous or oral etoposide. Ann Oncol 5:90-92, 1994
20. Raderer M, Kornek GV, Hejna MHL, et al: Treatment of advanced gastric cancer with oral etoposide, leucovorin and tegafur: Experience with an oral modification of the etoposide, leucovorin and 5-fluorouracil (ELF) regimen. Eur J Cancer 34:1128-1130, 1998
21. Chiou TJ, Tung SL, Hsieh RK, et al: Phase II study of the modified regimen of etoposide, leucovorin and 5-fluorouracil for patients with advanced gastric cancer. Jpn J Clin Oncol 28:318-322, 1998
22. Feliu J, González Barón M, García-Girón C, et al: Treatment of patients with advanced gastric carcinoma with the combination of etoposide plus oral tegafur modulated by uracil and leucovorin: A phase II study of the ONCOPAZ Cooperative Group. Cancer 78:211-216, 1996
23. Partyka S, Dumas P, Ajani J: Combination chemotherapy with granulocyte-macrophage-colony stimulating factor in patients with locoregional and metastatic gastric adenocarcinoma. Cancer 85:2336-2339, 1999
24. Preusser P, Wilke H, Achterrath W, et al: Phase II study with the combination etoposide, doxorubicin, and cisplatin in advanced measurable gastric cancer. J Clin Oncol 7:1310-1317, 1989
25. Wilke H, Preusser P, Fink U, et al: Preoperative chemotherapy in locally advanced and nonresectable gastric cancer: A phase II study with etoposide, doxorubicin, and cisplatin, J Clin Oncol 7:1318-1326, 1989
26. Kelsen D, Atiq OT, Saltz L, et al: FAMTX versus etoposide. doxorubicin, and cisplatin: A random assignment trial in gastric cancer. J Clin Oncol 10:541-548, 1992
27. Lacave AJ, Barón FJ, Antón LM, et al: Combination chemotherapy with cisplatin and 5-fluorouracil 5-day infusion in the therapy of advanced gastric cancer: A phase II trial. Ann Oncol 2:751-754, 1991
28. Rougier P, Ducreux M, Mahjoubi M, et al: Efficacy of combined 5-fluorouracil and cisplatinum in advanced gastric carcinomas: A phase II trial with prognostic factor analysis. Eur J Cancer 30:1263-1269, 1994
29. Pocock SJ, Simon R: Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 31:103-115, 1975
30. Bartolucci A: Estimation of comparison of proportions, in Buyse M, Staquet M, Sylvester R (eds): Cancer Clinical Trials, Methods and Practice. Oxford, United Kingdom, Oxford University Press, 1984, pp 337-360
31. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
32. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163-170, 1966
33. Cox DR: Regression models and life-tables. J R Stat Soc B 34:187-202, 1972
34. Vanhoefer U, Wilke H, Fink U, et al: Weekly 24 h-infusion of high dose FU (HD-FU) plus folinic acid (FA) plus biweekly cisplatin (C) (Group A) or HD-FU/FA/C plus epirubicin (E) (Group B) in locally advanced or metastatic gastric cancer. Proc Am Soc Clin Oncol 14:197a, 1995 (abstr 464)
35. Sulkes A, Smyth J, Sessa C: Docetaxel (taxotere) in advanced gastric cancer: Results of a phase II clinical trial - EORTC Early Clinical Trials Group. Br J Cancer 70:380-383, 1994
36. Vanhoefer U, Harstrick A, Wilke H, et al: Phase II study of docetaxel (D) as salvage chemotherapy in patients with advanced gastric cancer. Eur J Cancer 35:145, 1999 (suppl 4, 529)
37. Mai M, Sakata Y, Kanamarus R: A late phase II clinical study of RP56976 (docetaxel) in patients with advanced or recurrent gastric cancer: A Cooperative Study Group trial (Group B). Gan To Kagaku Ryoho 26:487-496, 1999
38. Futatsuki K, Wakui A, Nakao I: Late phase II study of irinotecan hydrochloride (CPT-11) in advanced gastric cancer: CPT-11 Gastrointestinal Cancer Study Group. Gan To Kagaku Ryoho 21:1033-1038, 1994
39. Shirao K, Shimada AY, Kondo H, et al: Phase I-II study of irinotecan hydrochloride combined with cisplatin in patients with advanced gastric cancer. J Clin Oncol 15:921-927, 1997